The diagnosis and management of CRS is crucial to patient health, and there is a wealth of evidence supporting the use of inhibitors of the IL-6 pathway, such as tocilizumab or siltuximab, to treat CRS [56]. Here, IL6 is linked to congenital rubella syndrome.